CNBX Pharmaceuticals Inc. financial data

Symbol
CNBX on OTC
Location
#3 Bethesda Metro Center, Suite 700, Bethesda, MD
Fiscal year end
August 31
Latest financial report
10-Q - Q2 2025 - Jul 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.2 % -80.6%
Return On Equity 8.89 % -83.6%
Return On Assets -730 % -70.8%
Operating Margin -1.1K % -628%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 92.5M shares +197%
Common Stock, Shares, Outstanding 92.5M shares +2873%
Entity Public Float 438K USD -75.8%
Common Stock, Value, Issued 9.25K USD +197%
Weighted Average Number of Shares Outstanding, Basic 42.6M shares +36.9%
Weighted Average Number of Shares Outstanding, Diluted 42.6M shares +36.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Cost of Revenue 0 USD -100%
Research and Development Expense -67.7K USD -119%
General and Administrative Expense 268K USD -52.1%
Operating Income (Loss) -194K USD +71.9%
Net Income (Loss) Attributable to Parent -224K USD +81.4%
Earnings Per Share, Basic 0 USD/shares -100%
Earnings Per Share, Diluted 0 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.6K USD -81.4%
Assets, Current 18.6K USD -76.7%
Property, Plant and Equipment, Net 0 USD
Assets 18.6K USD -76.7%
Liabilities, Current 2.56M USD +0.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -25.1M USD -0.9%
Stockholders' Equity Attributable to Parent -2.54M USD -3.38%
Liabilities and Equity 18.6K USD -76.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.1K USD +45.6%
Net Cash Provided by (Used in) Financing Activities 30K USD +20%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 1.8B shares +100%
Common Stock, Shares, Issued 92.5M shares +2873%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.08K USD +81.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.6K USD -81.4%
Deferred Tax Assets, Valuation Allowance 3.47M USD +3.86%
Depreciation 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -224K USD +80.5%
Deferred Tax Assets, Operating Loss Carryforwards 3.47M USD +3.86%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 22.6M USD +0.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%